Mind Medicine (MindMed) Inc.DFTXEarnings & Financial Report
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
DFTX Q4 2023 Key Financial Metrics
Revenue
$906.0K
Gross Profit
N/A
Operating Profit
$-22.2M
Net Profit
$-23.9M
Gross Margin
N/A
Operating Margin
-2450.8%
Net Margin
-2634.0%
YoY Growth
-16.1%
EPS
$-0.58
Financial Flow
Mind Medicine (MindMed) Inc. Q4 2023 Financial Summary
Mind Medicine (MindMed) Inc. reported revenue of $906.0K for Q4 2023, with a net profit of $-23.9M (-2634.0% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $906.0K |
|---|---|
| Net Profit | $-23.9M |
| Gross Margin | N/A |
| Operating Margin | -2450.8% |
| Report Period | Q4 2023 |
Mind Medicine (MindMed) Inc. Annual Revenue by Year
Mind Medicine (MindMed) Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $4.7M).
| Year | Annual Revenue |
|---|---|
| 2023 | $4.7M |
| 2022 | $1.5M |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $-27000 | $82000 | $360000 | $1.1M | $1.3M | $1.3M | $1.2M | $906000 |
| YoY Growth | 69.0% | N/A | 662.5% | N/A | 4855.6% | 1498.8% | 223.1% | -16.1% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $149.2M | $134.3M | $180.9M | $170.0M | $155.5M | $142.1M | $141.6M | $124.5M |
| Liabilities | $12.4M | $9.8M | $27.3M | $19.1M | $25.2M | $36.1M | $45.6M | $46.4M |
| Equity | $136.8M | $124.5M | $153.6M | $150.9M | $130.3M | $106.0M | $96.0M | $78.1M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-12.9M | $-15.1M | $-9.3M | $-12.8M | $-13.3M | $-13.8M | $-16.6M | $-20.6M |
More Companies
CRSP
CRISPR Therapeutics AG
Revenue
$864.0K
Net Profit
$-130.6M
GRAL
GRAIL, Inc.
Revenue
$36.2M
Net Profit
$-89.0M
RCUS
Arcus Biosciences, Inc.
Revenue
$6.0M
Net Profit
$-135.0M
TXG
10x Genomics, Inc.
Revenue
$166.0M
Net Profit
$-16.3M
PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Revenue
$38.4M
Net Profit
$-38.0M
ASMB
ASSEMBLY BIOSCIENCES, INC.
Revenue
$10.8M
Net Profit
$-9.2M
DTIL
PRECISION BIOSCIENCES INC
Revenue
$13.0K
Net Profit
$-21.8M